Compare PAGSEG Inc (PAGS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? PAGSEG Inc trades at $10.83 (market cap $3.03B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.5× PAGSEG Inc's market cap, and PAGSEG Inc pays a 10.19% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PAGSEG Inc for 27 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PAGS | SYRE | |
|---|---|---|
Market Cap | $3.03B | $7.52B |
Volume | 2,770,540 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $12.00 | $108.92 |
52-Week Low | $8.44 | $22.18 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $11.16B | $6.52B |
Dividend Yield | 10.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $10.99, down 1.35% on the day, with a bullish technical signal from moving averages but overbought short-term RSI readings. The company reported a Q2 2026 EPS beat of $0.41 vs. $0.389 expected, with revenue growth to $20.6B in 2026 and a net income margin of 10.45%. A dividend of $0.28 is scheduled for payment on September 30, 2026.
The stock presents a value opportunity with low P/E (7.31) and P/S (0.76) ratios, supported by strong analyst consensus (62.5% buy ratings) and a $10.70 price target. Key risks include macroeconomic pressures in Brazil and elevated credit losses, but robust cash flow and banking growth underpin long-term potential.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
